Does the media favor IONS or ZYME?

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Ionis Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.27 beat Ionis Pharmaceuticals' score of -0.42 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, IMVT or ZYME?

Zymeworks has higher revenue and earnings than Immunovant. Zymeworks is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Zymeworks $37.13M 48.28 -$81.13M -$2.02 N/A

Is IMVT or ZYME more profitable?

Immunovant has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Immunovant's return on equity of -69.59% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Zymeworks -405.31% -72.30% -37.18%

Does the media favor IMVT or ZYME?

In the previous week, Immunovant had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Immunovant and 2 mentions for Zymeworks. Immunovant's average media sentiment score of 0.69 beat Zymeworks' score of 0.27 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ZYME or ALKS?

Alkermes has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $37.13M 48.28 -$81.13M -$2.02 N/A Alkermes $1.48B 4.56 $241.66M $0.38 105.55

Is ZYME or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Zymeworks' net margin of -405.31%. Alkermes' return on equity of 4.15% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Alkermes 3.96% 4.15% 2.19%

Does the media favor ZYME or ALKS?

In the previous week, Alkermes had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Alkermes and 2 mentions for Zymeworks. Alkermes' average media sentiment score of 0.52 beat Zymeworks' score of 0.27 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or ZYME?

In the previous week, Iovance Biotherapeutics had 18 more articles in the media than Zymeworks. MarketBeat recorded 20 mentions for Iovance Biotherapeutics and 2 mentions for Zymeworks. Iovance Biotherapeutics' average media sentiment score of 0.76 beat Zymeworks' score of 0.27 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zymeworks (ZYME) Competitors

$25.79 +0.53 (+2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$25.79 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

ZYME vs. IONS, IMVT, ALKS, IOVA, and RYTM

Should you buy Zymeworks stock or one of its competitors? Zymeworks's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Immunovant (IMVT), Alkermes (ALKS), Iovance Biotherapeutics (IOVA), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zymeworks compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Ionis Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus target price of $89.20, indicating a potential upside of 106.00%. Zymeworks has a consensus target price of $40.64, indicating a potential upside of 60.87%. Given Ionis Pharmaceuticals' higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Ionis Pharmaceuticals has a net margin of -64.76% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Zymeworks	-405.31%	-72.30%	-37.18%

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Ionis Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.27 beat Ionis Pharmaceuticals' score of -0.42 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zymeworks has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.62	-$381.39M	-$3.46	N/A
Zymeworks	$37.13M	48.28	-$81.13M	-$2.02	N/A

Summary

Zymeworks beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 1.9% of Immunovant shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Immunovant had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Immunovant and 2 mentions for Zymeworks. Immunovant's average media sentiment score of 0.69 beat Zymeworks' score of 0.27 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Immunovant presently has a consensus price target of $44.00, indicating a potential upside of 45.41%. Zymeworks has a consensus price target of $40.64, indicating a potential upside of 60.87%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Immunovant has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Immunovant's return on equity of -69.59% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Zymeworks	-405.31%	-72.30%	-37.18%

Zymeworks has higher revenue and earnings than Immunovant. Zymeworks is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Zymeworks	$37.13M	48.28	-$81.13M	-$2.02	N/A

Summary

Zymeworks beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Alkermes?

Zymeworks (NASDAQ:ZYME) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Zymeworks has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Zymeworks currently has a consensus target price of $40.64, suggesting a potential upside of 60.87%. Alkermes has a consensus target price of $54.47, suggesting a potential upside of 35.80%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

In the previous week, Alkermes had 5 more articles in the media than Zymeworks. MarketBeat recorded 7 mentions for Alkermes and 2 mentions for Zymeworks. Alkermes' average media sentiment score of 0.52 beat Zymeworks' score of 0.27 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$37.13M	48.28	-$81.13M	-$2.02	N/A
Alkermes	$1.48B	4.56	$241.66M	$0.38	105.55

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alkermes has a net margin of 3.96% compared to Zymeworks' net margin of -405.31%. Alkermes' return on equity of 4.15% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Zymeworks on 11 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Iovance Biotherapeutics has a net margin of -89.11% compared to Zymeworks' net margin of -405.31%. Iovance Biotherapeutics' return on equity of -40.51% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Zymeworks	-405.31%	-72.30%	-37.18%

In the previous week, Iovance Biotherapeutics had 18 more articles in the media than Zymeworks. MarketBeat recorded 20 mentions for Iovance Biotherapeutics and 2 mentions for Zymeworks. Iovance Biotherapeutics' average media sentiment score of 0.76 beat Zymeworks' score of 0.27 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zymeworks has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	18.55	-$390.98M	-$0.73	N/A
Zymeworks	$37.13M	48.28	-$81.13M	-$2.02	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Iovance Biotherapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Iovance Biotherapeutics currently has a consensus target price of $12.90, suggesting a potential downside of 3.08%. Zymeworks has a consensus target price of $40.64, suggesting a potential upside of 60.87%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Zymeworks beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Zymeworks has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	25.61	-$196.54M	-$3.11	N/A
Zymeworks	$37.13M	48.28	-$81.13M	-$2.02	N/A

92.9% of Zymeworks shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals presently has a consensus price target of $140.89, suggesting a potential upside of 57.17%. Zymeworks has a consensus price target of $40.64, suggesting a potential upside of 60.87%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Rhythm Pharmaceuticals has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

In the previous week, Zymeworks had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 2 mentions for Zymeworks and 0 mentions for Rhythm Pharmaceuticals. Zymeworks' average media sentiment score of 0.27 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Zymeworks	Neutral

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Zymeworks	-405.31%	-72.30%	-37.18%

Summary

Zymeworks beats Rhythm Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	-12.77	13.42	274.13	26.16
Price / Sales	17.27	1,212.26	581.78	94.37
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	7.18	17.17	11.21	6.34
Net Income	-$81.13M	-$22.69M	$3.50B	$381.90M
7 Day Performance	2.54%	-1.20%	-0.84%	-1.39%
1 Month Performance	-5.01%	-9.68%	-5.42%	-4.31%
1 Year Performance	52.42%	10.09%	4.38%	-0.35%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	2.6825 of 5 stars	$25.79 +2.1%	$40.64 +57.6%	+51.4%	$1.79B	$105.96M	N/A	264	Analyst Forecast Insider Trade
IONS Ionis Pharmaceuticals	3.2032 of 5 stars	$43.54 -1.0%	$89.20 +104.9%	-38.1%	$7.31B	$944M	N/A	1,402
IMVT Immunovant	2.5642 of 5 stars	$33.62 -0.1%	$44.00 +30.9%	+88.2%	$6.94B	N/A	N/A	315	Insider Trade
ALKS Alkermes	3.4642 of 5 stars	$41.75 +3.0%	$54.47 +30.5%	+27.3%	$6.80B	$1.48B	109.87	2,050
IOVA Iovance Biotherapeutics	2.3886 of 5 stars	$14.22 -0.1%	$12.40 -12.8%	+486.3%	$6.45B	$324.97M	N/A	975	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. IONS, IMVT, ALKS, IOVA, and RYTM

How does Zymeworks compare to Ionis Pharmaceuticals?

Summary

How does Zymeworks compare to Immunovant?

Summary

How does Zymeworks compare to Alkermes?

Summary

How does Zymeworks compare to Iovance Biotherapeutics?

Summary

How does Zymeworks compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. IONS, IMVT, ALKS, IOVA, and RYTM

How does Zymeworks compare to Ionis Pharmaceuticals?

Which has more volatility & risk, IONS or ZYME?

Do analysts prefer IONS or ZYME?

Is IONS or ZYME more profitable?

Does the media favor IONS or ZYME?

Do institutionals and insiders have more ownership in IONS or ZYME?

Which has stronger valuation & earnings, IONS or ZYME?

Summary

How does Zymeworks compare to Immunovant?

Do institutionals and insiders have more ownership in IMVT or ZYME?

Does the media favor IMVT or ZYME?

Which has more risk and volatility, IMVT or ZYME?

Do analysts prefer IMVT or ZYME?

Is IMVT or ZYME more profitable?

Which has stronger valuation & earnings, IMVT or ZYME?

Summary

How does Zymeworks compare to Alkermes?

Which has more volatility and risk, ZYME or ALKS?

Do analysts prefer ZYME or ALKS?

Does the media favor ZYME or ALKS?

Which has preferable earnings and valuation, ZYME or ALKS?

Do institutionals & insiders have more ownership in ZYME or ALKS?

Is ZYME or ALKS more profitable?

Summary

How does Zymeworks compare to Iovance Biotherapeutics?

Is IOVA or ZYME more profitable?

Does the media refer more to IOVA or ZYME?

Which has preferable earnings and valuation, IOVA or ZYME?

Do insiders and institutionals hold more shares of IOVA or ZYME?

Which has more volatility & risk, IOVA or ZYME?

Do analysts recommend IOVA or ZYME?

Summary

How does Zymeworks compare to Rhythm Pharmaceuticals?

Which has better earnings & valuation, RYTM or ZYME?

Do institutionals and insiders hold more shares of RYTM or ZYME?

Do analysts rate RYTM or ZYME?

Which has more volatility & risk, RYTM or ZYME?

Does the media refer more to RYTM or ZYME?

Is RYTM or ZYME more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools